Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer

CAMBRIDGE, Mass., Oct. 02, 2017 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the promotion of Dr. Ganesh Kaundinya to Chief Operating Officer. Dr. Kaundinya, who assumed his new position effective September 25, 2017, will also continue to serve as Chief Scientific Officer and report directly to Craig Wheeler, Momenta’s President and Chief Executive Officer.

“As one of our founders, Ganesh has been a cornerstone at Momenta since its inception. Ganesh has achieved a great track record of success and in this new role I believe his passion for the business, our strategic partnerships, and the impact we can have on patients’ lives will play an even more integral role in driving our business forward,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals.

In addition to his role as Chief Scientific Officer, Dr. Kaundinya will oversee the operational management of research and development, manufacturing, commercial activities, and program and alliance management.

Ganesh Kaundinya added, “I am very excited to take on this expanded role at Momenta as we continue to advance our robust portfolio of biosimilar and novel drug candidates that have the potential to address the unmet medical needs of the patients we look to serve, as well as create significant value for our shareholders and employees.”

Prior to founding Momenta, Dr. Kaundinya was a member of the MIT faculty where he pioneered research in the areas of analytical techniques for complex molecules and extracellular matrix regulation of cell biology.  He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-million dollar NIH initiative to study the role of complex sugars in biology.  Dr. Kaundinya received both his M.S. and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Kaundinya’s expected impact and duties, and statements about the Company’s drug candidates and the ability of the Company’s drug candidates to address the unmet medical needs of patients and create significant value for our shareholders and employees. Forward-looking statements may be identified by words such as "believe," "continue," "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]

MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
[email protected]